NASDAQ:MRSN - Mersana Therapeutics Stock Price, Price Target & More

Mersana Therapeutics trades on the NASDAQ under the ticker symbol "MRSN."

Mersana Therapeutics Inc (NASDAQ:MRSN) announced its earnings results on Monday, May, 14th. The company reported ($0.54) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.61) by $0.07. The firm had revenue of $3.06 million for the quarter, compared to analysts' expectations of $3.49 million. Mersana Therapeutics had a negative return on equity of 124.32% and a negative net margin of 263.80%. View Mersana Therapeutics' Earnings History.

6 brokers have issued 1-year price targets for Mersana Therapeutics' shares. Their predictions range from $16.00 to $61.00. On average, they expect Mersana Therapeutics' share price to reach $31.00 in the next year. This suggests a possible upside of 185.2% from the stock's current price. View Analyst Ratings for Mersana Therapeutics.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mersana Therapeutics in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to Mersana Therapeutics include Dynavax Technologies (DVAX), CytomX Therapeutics (CTMX), Omeros (OMER), TG Therapeutics Inc common stock (TGTX), Karyopharm Therapeutics (KPTI), MacroGenics (MGNX), AC Immune (ACIU), Epizyme (EPZM), OptiNose (OPTN), Rhythm Pharmaceuticals (RYTM), Assembly Biosciences (ASMB), ANI Pharmaceuticals Inc Common Stock (ANIP), Amarin (AMRN), Homology Medicines (FIXX) and Rocket Pharmaceuticals (RCKT).

(MRSN) raised $75 million in an initial public offering (IPO) on Wednesday, June 28th 2017. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

News stories about MRSN stock have trended very positive recently, Accern reports. Accern scores the sentiment of press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Mersana Therapeutics earned a media sentiment score of 0.51 on Accern's scale. They also gave media headlines about the company an impact score of 48.24 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term.

Shares of MRSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of MRSN stock can currently be purchased for approximately $10.87.

Mersana Therapeutics has a market capitalization of $248.94 million and generates $17.55 million in revenue each year. The company earns $-38,700,000.00 in net income (profit) each year or ($3.22) on an earnings per share basis. Mersana Therapeutics employs 78 workers across the globe.

Mersana Therapeutics' mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-498-0020 or via email at [email protected]